Patents by Inventor Brian C. Froehler

Brian C. Froehler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8653248
    Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: February 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
  • Patent number: 6756496
    Abstract: Novel hydrogen-phosphonodithioate compositions are provided which are particularly useful for forming internucleotide and internucleoside linkages in oligonucleosides or oligonucleotides. The oligonucleotides and analogs thereof made by using the hydrogen-phosphonodithioate compositions may be therapeutically useful as antiviral and anticancer agents and may have other therapeutic or diagnostic uses. A method for making the hydrogen-phosphonodithioates is provided as well as a method for converting same to an activated intermediate for substitution on the phosphorus atom.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: June 29, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brian C. Froehler, Chris A. Buhr
  • Publication number: 20030120065
    Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.
    Type: Application
    Filed: June 13, 2002
    Publication date: June 26, 2003
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
  • Patent number: 6495672
    Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: December 17, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
  • Patent number: 6447998
    Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: September 10, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
  • Patent number: 5565555
    Abstract: Novel hydrogen-phosphonodithioate compositions are provided which are particularly useful for forming internucleotide and internucleoside linkages in oligonucleosides or oligonucleotides, The oligonucleotides and analogs thereof made by using the hydrogen-phosphonodithioate compositions may be therapeutically useful as antiviral and anticancer agents and may have other therapeutic or diagnostic uses, A method for making the hydrogen-phosphonodithioates is provided as well as a method for converting same to an activated intermediate for substitution on the phosphorus atom.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: October 15, 1996
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian C. Froehler, Chris A. Buhr
  • Patent number: 5548076
    Abstract: A method is provided for the high fidelity, rapid and economical in vitro synthesis of oligonucleotides. Nucleoside H-phosphonates are condensed in seriatim using a dehydrating agent to produce a poly (nucleoside H-phosphonate). The product is oxidized to yield the desired oligonucleotide. A novel reagent is provided for multiple nucleoside additions in single cycles.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: August 20, 1996
    Assignee: Genentech, Inc.
    Inventors: Brian C. Froehler, Mark D. Matteucci
  • Patent number: 5264566
    Abstract: A method is provided for the high fidelity, rapid and economical in vitro synthesis of oligonucleotides. Nucleoside H-phosphonates are condensed in seriatim using a dehydrating agent to produce a poly (nucleoside H-phosphonate). The product is oxidized to yield the desired oligonucleotide. A novel reagent is provided for multiple nucleoside additions in single cycles.
    Type: Grant
    Filed: April 26, 1990
    Date of Patent: November 23, 1993
    Assignee: Genentech, Inc.
    Inventors: Brian C. Froehler, Mark D. Matteucci
  • Patent number: 5256775
    Abstract: A method is provided for making 3' and/or 5' end-capped oligonucleotides so as to render the oligonucleotide resistant to degradation by exonucleases. The exonuclease degradation resistance is provided by incorporating two or more phosphoramidate and phosphorocmonothioate and/or phosphorodithioate linkages at the 5' and/or 3' ends of the oligonucleotide, wherein the number of phosphoramidate linkages is less than a number which would interfere with hybridization to a complementary oligonucleotide strand and/or which would interfere with RNAseH activity when the oligonucleotide is hybridized to RNA.
    Type: Grant
    Filed: June 5, 1990
    Date of Patent: October 26, 1993
    Assignee: Gilead Sciences, Inc.
    Inventor: Brian C. Froehler
  • Patent number: 5204455
    Abstract: The present invention describes methods for the production of oligonucleotides under conditions which exploit the desirable characteristics, such as the property of sustaining high degrees of substitution, of functionalized organic polymeric supports while avoiding the sluggish kinetics and low rates of conversion which normally plague syntheses involving such solid supports. By employing the methods and materials disclosed, functionalized support, substituted to a degree of about 250 .mu.mol/g, can be utilized at greater than 98% conversion levels for each sequential nucleotide coupling cycle, to provide unprecedented amounts of isolated oligonucleotide per gram of solid support.
    Type: Grant
    Filed: February 10, 1992
    Date of Patent: April 20, 1993
    Inventors: Brian C. Froehler, Kenneth M. Kent, Sylvia Wu
  • Patent number: 5194599
    Abstract: Novel hydrogen-phosphonodithioate compositions are provided which are particularly useful for forming internucleotide and internucleoside linkages in oligonucleosides or oligonucleotides. The oligonucleotides and analogs thereof made by using the hydrogen-phosphonodithioate compositions may be therapeutically useful as antiviral and anticancer agents and may have other therapeutic or diagnostic uses. A method for making the hydrogen-phosphonodithioates is provided as well as a method for converting same to an activated intermediate for substitution on the phosphorus atom.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: March 16, 1993
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian C. Froehler, Chris A. Buhr
  • Patent number: 5164491
    Abstract: The present invention describes methods for the production of oligonucleotides under conditions which exploit the desirable characteristics, such as the property of sustaining high degrees of substitution, of functionalized organic polymeric supports while avoiding the sluggish kinetics and low rates of conversion which normally plague syntheses involving such solid supports. By employing the methods and materials disclosed, functionalized support, substituted to a degree of about 250 .mu.mol/g, can be utilized at greater than 98% conversion levels for each sequential nucleotide coupling cycle, to provide unprecedented amounts of isolated oligonucleotide per gram of solid support.
    Type: Grant
    Filed: June 15, 1989
    Date of Patent: November 17, 1992
    Assignee: Gilead Sciences
    Inventors: Brian C. Froehler, Kenneth M. Kent, Sylvia Wu
  • Patent number: 4959463
    Abstract: A method is provided for the high fidelity, rapid and economical in vitro synthesis of oligonucleotides. Nucleoside H-phosphonates are condensed in seriatim using a dehydrating agent to produce a poly (nucleoside H-phosphonate). The produce is oxidized to yield the desired oligonucleotide. A novel reagent is provided for multiple nucleoside additions in single cycles.
    Type: Grant
    Filed: September 19, 1986
    Date of Patent: September 25, 1990
    Assignee: Genentech, Inc.
    Inventors: Brian C. Froehler, Mark D. Matteucci